TY - JOUR
T1 - Signal transduction inhibition
T2 - Results from phase I clinical trials in chronic myeloid leukemia
AU - Druker, Brian
PY - 2001
Y1 - 2001
N2 - The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98%) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20% of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.
AB - The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98%) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20% of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.
UR - http://www.scopus.com/inward/record.url?scp=0034868659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034868659&partnerID=8YFLogxK
U2 - 10.1016/s0037-1963(01)90112-x
DO - 10.1016/s0037-1963(01)90112-x
M3 - Review article
C2 - 11526596
AN - SCOPUS:0034868659
SN - 0037-1963
VL - 38
SP - 9
EP - 14
JO - Seminars in hematology
JF - Seminars in hematology
IS - 3 SUPPL. 8
ER -